Evidence map›Paper›PMID 36036789›Full record

ArticleThe FEBS journal2023

Structure-based design, synthesis and biological evaluation of a NAD

Rahila Rahimova, Pauline Nogaret, Valérie Huteau, Muriel Gelin, David A Clément, Gilles Labesse, Sylvie Pochet, Anne-Béatrice Blanc-Potard, Corinne Lionne

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The FEBS journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rahila RahimovaCentre de Biologie Structurale (CBS), Université de Montpellier, CNRS UMR 5048, INSERM U1054, France.
Pauline NogaretLaboratory of Pathogen Host Interactions (LPHI), Université de Montpellier, CNRS UMR 5235, France.
Valérie HuteauUnité de Chimie Biologique Epigénétique, Institut Pasteur, Université Paris Cité, CNRS UMR3523, France.
Muriel GelinCentre de Biologie Structurale (CBS), Université de Montpellier, CNRS UMR 5048, INSERM U1054, France.
David A ClémentUnité de Chimie Biologique Epigénétique, Institut Pasteur, Université Paris Cité, CNRS UMR3523, France.
Gilles LabesseCentre de Biologie Structurale (CBS), Université de Montpellier, CNRS UMR 5048, INSERM U1054, France.
Sylvie PochetUnité de Chimie Biologique Epigénétique, Institut Pasteur, Université Paris Cité, CNRS UMR3523, France.
Anne-Béatrice Blanc-PotardLaboratory of Pathogen Host Interactions (LPHI), Université de Montpellier, CNRS UMR 5235, France.
Corinne LionneCentre de Biologie Structurale (CBS), Université de Montpellier, CNRS UMR 5048, INSERM U1054, France.ORCID 0000-0002-6348-5311
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance is a major public health problem that requires the urgent development of new antibiotics and therefore the identification of novel bacterial targets. The activity of nicotinamide adenine dinucleotide kinase, NADK, is essential in all bacteria tested so far, including many human pathogens that display antibiotic resistance leading to the failure of current treatments. Inhibiting NADK is therefore a promising and innovative antibacterial strategy since there is currently no drug on the market targeting this enzyme. Through a fragment-based drug design approach, we have recently developed a NAD

Indexed as

Anti-Bacterial AgentsNADPseudomonas aeruginosaAnimalsDrug DesignPhosphotransferases (Alcohol Group Acceptor)ZebrafishAnti-Bacterial AgentsNADNAD kinasePhosphotransferases (Alcohol Group Acceptor)antibioticsbenzamide adenine dinucleoside analogueESKAPEnew target enzymezebrafish

Identifiers

PMID36036789
PMCPMC10087438
OpenAlexW4293462501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.